A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles

Pharmaceutical Research

Volumn 28, Issue 3, 2011, Pages 662-672

  Lim, Sok Bee ^a   Rubinstein, Israel ^a,c   Sadikot, Ruxana T ^a,c   Artwohl, James E ^a   Önyüksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

acute lung injury; anti inflammation; GLP 1; gram negative sepsis; PEGylated phospholipid micelles

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INTERLEUKIN 6; MYELOPEROXIDASE; PHOSPHOLIPID;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME ACTIVITY; FLUORESCENCE SPECTROSCOPY; HYDRODYNAMICS; IN VIVO STUDY; MICELLE; MOUSE; NANOMEDICINE; NEUTROPHIL COUNT; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; UPREGULATION;

ACUTE LUNG INJURY; ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION MEDIATORS; LUNG; MICE; MICE, INBRED C57BL; MICELLES; NANOMEDICINE; PHOSPHOLIPIDS; RATS;

EID: 79952487368     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0322-4     Document Type: Article

References (38)

1. Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, et al. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide. Crit Care Med. 2006;34(12):2883-90. (Pubitemid 44808728)
2. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest. 2007;131(2):554-62. (Pubitemid 46280419)
3. Bosma KJ, Lewis JF. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007;12(3):461-77. (Pubitemid 47518379)
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. (Pubitemid 350041474)
5. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of proinflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol. 2008;41(1):35-44.
6. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55(4):352-60. (Pubitemid 43866249)
7. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. (Pubitemid 46711096)
8. Lee KC, Chae SY, Kim TH, Lee S, Lee ES, Youn YS. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept. 2009;152(1-3):101-7.
9. Yin D, Lu Y, Zhang H, Zhang G, Zou H, Sun D, et al. Preparation of glucagon-like peptide-1 loaded PLGA micro-spheres: characterizations, release studies and bioactivities in vitro/in vivo. Chem Pharm Bull. 2008;56(2):156-61. (Pubitemid 351206637)
10. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diab Care. 2009;32(2):e22-3.
11. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract. 2009;63(2):321-32.
12. Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93(10):2476-87.
13. Lim SB, Rubinstein I, Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm. 2008;356(1-2):345-50.
14. Sethi V, Onyuksel H, Rubinstein I. Enhanced circulation half-life and reduced clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized phospholipid micelles (SSM) in mice with collagen-induced arthritis (CIA). AAPS PharmSci. 2003;5 Suppl 1:M1045.
15. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1(3):193-212. (Pubitemid 43963632)
16. Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine: addressing unmet medical need in acute lung injury. J Biomed Nanotechnol. 2009;5(6):614-9.
17. Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir. 2005;21(8):3279-90. (Pubitemid 40538337)
18. Stark A, Mentlein R. Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells. Regul Pept. 2002;108(2-3):97-102. (Pubitemid 35239865)
19. John H, Maronde E, Forssmann WG, Meyer M, Adermann K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP-and insulin-releasing capacity. Eur J Med Res. 2008;13(2):73-8.
20. Ingenito EP, Mora R, Cullivan M, Marzan Y, Haley K, Mark L, et al. Decreased surfactant protein-B expression and surfactant dysfunction in a murine model of acute lung injury. Am J Respir Cell Mol Biol. 2001;25(1):35-44. (Pubitemid 32682703)
21. Baron RM, Carvajal IM, Fredenburgh LE, Liu X, Porrata Y, Cullivan ML, et al. Nitric oxide synthase-2 down-regulates surfactant protein-B expression and enhances endotoxin-induced lung injury in mice. FASEB J. 2004;18(11):1276-8. (Pubitemid 39561575)
22. Yull FE, Han W, Jansen ED, Everhart MB, Sadikot RT, Christman JW, et al. Bioluminescent detection of endotoxin effects on HIV-1 LTR-driven transcription in vivo. J Histochem Cytochem. 2003;51(6):741-9. (Pubitemid 36628855)
23. Jeyaseelan S, Chu HW, Young SK, Worthen GS. Transcriptional profiling of lipopolysaccharide-induced acute lung injury. Infect Immun. 2004;72(12):7247-56. (Pubitemid 39552396)
24. Krishnadas A, Onyuksel H, Rubinstein I. Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr Pharm Des. 2003;9(12):1005-12.
25. Bourbigot S, Dodd E, Horwood C, Cumby N, Fardy L, Welch WH, et al. Antimicrobial peptide RP-1 structure and interactions with anionic versus zwitterionic micelles. Biopolymers. 2009;91(1):1-13.
26. Tinoco LW, Gomes-Neto F, Valente AP, Almeida FC. Effect of micelle interface on the binding of anticoccidial PW2 peptide. J Biomol NMR. 2007;39(4):315-22. (Pubitemid 350055753)
27. Sadikot RT, Jansen ED, Blackwell TR, Zoia O, Yull F, Christman JW, et al. High-dose dexamethasone accentuates nuclear factor-kappa b activation in endotoxin-treated mice. Am J Respir Crit Care Med. 2001;164(5):873-8. (Pubitemid 32881927)
28. Bream-Rouwenhorst HR, Beltz EA, Ross MB, Moores KG. Recent developments in the management of acute respiratory distress syndrome in adults. Am J Health Syst Pharm. 2008;65(1):29-36.
29. Sato Y. Modulation of PMN-endothelial cells interactions by cyclic nucleotides. Curr Pharm Des. 2004;10(2):163-70. (Pubitemid 38072752)
30. Stephens CG, Snyderman R. Cyclic nucleotides regulate the morphologic alterations required for chemotaxis in monocytes. J Immunol. 1982;128(3):1192-7. (Pubitemid 12188436)
31. Harvath L, Robbins JD, Russell AA, Seamon KB. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. J Immunol. 1991;146(1):224-32.
32. Tsushima K, King LS, Aggarwal NR, De Gorordo A, D'Alessio FR, Kubo K. Acute lung injury review. Intern Med. 2009;48(9):621-30.
33. Koo OM. A novel nanomedicine against arthritis: targeted camptothecin phospholipid micelles. PhD Thesis, University of Illinois at Chicago; 2006.
34. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. (Pubitemid 46048557)
35. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diab Care. 2001;24(8):1416-21. (Pubitemid 33716430)
36. Chen HI, Yeh DY, Liou HL, Kao SJ. Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med. 2006;34(3):758-64.
37. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med. 2008;36(8):2407-13.
38. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885-91. (Pubitemid 36019643)